Estrella Immunopharma, Inc.
ESLA
$1.72
$0.148.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | 09/30/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.41% | -163.50% | 14.54% | 14.54% | 14.54% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.96% | 0.00% | -- | -- | -- |
| Change in Net Operating Assets | -22.46% | 236.05% | -68.32% | -68.32% | -68.32% |
| Cash from Operations | -75.30% | 10.97% | -660.72% | -660.72% | -660.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -22.22% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 44.32% | 44.32% | 44.32% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.25% | -- | -- | -- | -- |
| Cash from Financing | -20.82% | 4,540.68% | 44.32% | 44.32% | 44.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -65.37% | 280.68% | -321.41% | -321.41% | -321.41% |